Condition: Epidermolysis Bullosa (EB) · Dystrophic Epidermolysis Bullosa · Junctional Epidermolysis Bullosa · Sponsor: Xinnate AB
This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, a pair of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.
This description comes directly from the study's public registry record.
Head of Clinical Development · 46462756000 · info@xinnate.com
Always discuss trial participation with your own doctor first.
| Hopital St Louis | Paris, France | Recruiting |
| Andreas Syngros Hospital of Veneral & Dermatological Diseases | Athens, Greece | Recruiting |
| Hospital Of Skin And Venereal Diseases of Thessaloniki | Thessaloniki, Greece | Recruiting |
| IDI Istituto Dermopatico dell'Immacolata IRCCS | Rome, Italy | Recruiting |
| San Joan de Deu, SJD Children's hospital Barcelona | Barcelona, Catalonia, Spain | Recruiting |
| Hospital Clinic de Barcelona | Barcelona, Spain | Recruiting |
| Hospital Univ La Paz | Madrid, Spain | Recruiting |
| University hospital | Lund, Skåne County, Sweden | Not Yet Recruiting |
| Akademiska sjukhuset | Uppsala, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06594393